Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium
- Written by ACN Newswire - Press Releases
TOKYO, Jan 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15
Read more //?#